ABSTRACT INTRODUCTION Early detection of cognitive decline in Alzheimer's disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often require lengthy in‐person visits, and may therefore limit scalability for younger, trial‐ready populations for primary and secondary prevention studies. We evaluated the feasibility, reliability, and validity of high‐frequency remote digital cognitive assessments in individuals with autosomal dominant AD (ADAD). METHODS One hundred twenty‐three mutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network Trials Unit from 20 international sites (Ages 19–66 years) completed remote assessments via personal smartphones, prompted four times daily for 7 days (≈ 3 minutes per session), and conventional in‐clinic cognitive testing at baseline. Adherence, between‐person reliability, test–retest reliability (intraclass correlation coefficients [ICCs]), construct validity (confirmatory factor analysis), and sensitivity to clinical disease progression were evaluated. RESULTS Remote measures demonstrated excellent reliability (ICCs > 0.90 after just 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. A composite of the remote tests slightly outperformed a traditional composite at separating mutation carriers from non‐carriers. Average adherence to the study protocol was 42%, lower that observed in previous studies of older adults. DISCUSSION High‐frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. This approach offers substantial utility for clinical trials, including improved accessibility and enhanced reliability, supporting its integration into early‐intervention studies.
A. Aschenbrenner, H. Wilks, Matthew S. Welhaf et al.· Alzheimer's & Dementia· 1 citation
Abstract INTRODUCTION The Mild Behavioral Impairment Checklist (MBI‐C) captures neuropsychiatric symptoms in individuals at risk of dementia. In this study, we examined MBI‐C scores in autosomal dominant Alzheimer's disease (ADAD). METHODS We included 83 cognitively unimpaired presenilin‐1 E280A mutation carriers and 114 non‐carriers with MBI‐C, obfjective cognition, and subjective cognitive decline (SCD) assessments. Study sub‐samples underwent neuroimaging to assess Alzheimer's disease (AD) pathology and neurodegeneration. RESULTS MBI‐C total scores were greater in carriers than non‐carriers (r rb = 0.19 [95% confidence interval (CI) 0.05, 0.31], P = 0.009), driven by impulse dyscontrol symptoms. Elevated MBI‐C scores were associated with higher study partner–reported SCD scores (β = 0.28 [95% CI 0.07, 0.050], P = 0.008) and with greater neocortical amyloid beta (β = 0.46 [95% CI 0.17, 0.075], P = 0.003) among carriers. DISCUSSION Our study reveals that mild behavioral impairment symptoms may emerge before cognitive decline in ADAD and supports the MBI‐C as a tool for detecting early behavioral changes linked to AD pathology and identifying at‐risk individuals for clinical trials and early intervention.
Catarina Tristão-Pereira, D. Vásquez, Jorge Alcina et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.